Helix Acquisition Corp. II
HLXB
NASDAQ Global Market9.90
USD
-0.16
- -
CIK
0001869105
ISIN
KYG4444H1011
CUSIP
107924102
Return %
Stock
S&P500
1Y
-5.17
26.53
3Y
-2.85
76.60
5Y
-2.85
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Bihua Chen
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 200 Clarendon Street Boston MA United States of America 02116
- IPO Date
- Feb 9, 2024
- CIK
- 0001869105
- Similar Companies
- Business
- Helix Acquisition Corp. II (Nasdaq: HLXB) operates as a special purpose acquisition company formed to effect mergers, capital stock exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more businesses, with a strategic focus on opportunities in healthcare and healthcare-related industries. The company does not currently manufacture or sell products or provide services beyond pursuing and executing its initial business combination; it holds cash in trust from its initial public offering for deployment in a target acquisition. Helix Acquisition Corp. II, sponsored by affiliates of Cormorant Asset Management, raised $184 million in its initial public offering on February 13, 2024, issuing 18.4 million Class A ordinary shares priced at $10.00 each, plus a concurrent private placement of 509,000 shares; the company originated as a Cayman Islands exempted entity on June 15, 2021, and is headquartered in Boston, Massachusetts. In its most significant recent development, Helix Acquisition Corp. II completed a business combination with BridgeBio Oncology Therapeutics, Inc. (BBOT), also known as TheRas, Inc., on August 11, 2025, resulting in Helix ceasing to exist as a standalone shell company and changing its name to BridgeBio Oncology Therapeutics, Inc., with the combined entity's common stock listing on Nasdaq under the ticker BBOT beginning August 12, 2025. Prior to closing, the parties announced the definitive agreement on February 27, 2025, alongside commitments for a $260 million private investment in public equity (PIPE) from institutional investors including Cormorant Asset Management, ADAR1 Capital Management, BC Capital, Deerfield Management, Novo Holdings, and Wellington Management; on August 5, 2025, Helix reported retaining over 60% of its trust account, or approximately $120 million net of redemptions—the second-lowest redemption rate for a biotech de-SPAC since 2022—yielding total gross proceeds of about $382 million including the PIPE to fund BBOT's clinical-stage pipeline of small molecule therapeutics targeting RAS and PI3Kα malignancies. The transaction, approved by shareholders including charter and bylaw amendments, domesticated the entity to Delaware and positions the post-merger company for oncology therapeutics advancement, with no further standalone operations or products under the HLXB ticker.
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines